Mengonfirmasi Anda bukan dari AS atau Filipina

Dengan memberikan pernyataan ini, saya secara tegas menyatakan dan mengonfirmasikan bahwa:
  • Saya bukan warga negara atau penduduk AS
  • Saya bukan penduduk Filipina
  • Saya, secara langsung maupun tidak langsung, tidak memiliki lebih dari 10% saham/hak suara/kepentingan dari penduduk AS dan/atau tidak mengontrol warga negara atau penduduk AS dengan cara lain
  • Saya tidak berada di bawah kepemilikan langsung atau tidak langsung untuk lebih dari 10% saham/hak suara/kepentingan dan/atau berada di bawah kontrol warga negara atau penduduk AS dengan cara lain
  • Saya tidak berafiliasi dengan warga negara atau penduduk AS dalam hal Bagian 1504(a) dari FATCA
  • Saya menyadari tanggung jawab saya jika membuat pernyataan palsu.
Untuk tujuan pernyataan ini, semua negara dan wilayah dependen AS disamakan dengan wilayah utama AS. Saya berkomitmen untuk membela dan membebaskan Octa Markets Incorporated, direktur dan pejabatnya dari klaim apa pun yang timbul akibat atau terkait dengan pelanggaran apa pun atas pernyataan saya.
Kami berkomitmen menjaga privasi dan keamanan informasi pribadi Anda. Kami hanya mengumpulkan email untuk menyediakan penawaran khusus dan informasi penting tentang produk dan layanan kami. Dengan memberikan alamat email, Anda setuju untuk menerima surat tersebut dari kami. Jika Anda ingin berhenti berlangganan atau memiliki pertanyaan maupun permasalahan, silakan hubungi Layanan Pelanggan kami.
Octa trading broker
Buka akun trading
Back

Gilead Sciences: Phase 3 trial shows significantly greater clinical improvement on 5-day Remdesivir treatment

Gilead Sciences announced the results from the phase three trial of Remdesivir in patients with moderate COVID-19 infection. Below are key takeaways, as reported by Reuters.

"Phase 3 trial demonstrates a 5-day treatment course of Remdesivir resulted in significantly greater clinical improvement vs standard of care alone."

"Remdesivir was generally well-tolerated in both 5-day and 10-day treatment groups."

"Non-statistically significant increases in clinical worsening/death observed in the standard of care only group compared with Remdesivir groups."

"Study demonstrated that patients in the 5-day Remdesivir treatment group were 65% more likely to have clinical improvement at day 11."

"Odds of improvement in clinical status with a 10-day course of Remdesivir were trending toward but not reaching statistical significance."

"Gilead Sciences Inc plans to submit full data from phase 3 simple trial of Remdesivir for publication in a peer-reviewed journal in coming weeks."

"At day 11, more proportion of patients in the 5-day group of Remdesivir met improvement in clinical status vs standard of care group."

"No new safety signals were identified with Remdesivir across either treatment group."

Market reaction

This statement doesn't seem to be having a significant impact on market sentiment. As of writing, the S&P 500 futures were down 0.23% on a daily basis.

UK PM Johnson spokesman: We hope latest round of Brexit talks will be constructive

"We hope the latest round of Brexit talks will be constructive and keep the process on track," British Prime Minister Boris Johnson's spokesman said o
Baca selengkapnya Previous

UK's Sunak: Slowly we are going to get our lives back to normal

"Slowly, we are going to get our lives back to normal," British finance minister Rishi Sunak said on Monday. "Getting our lives back to normal is not
Baca selengkapnya Next